AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
dinoprost 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| prostaglandins | 912 | 551-11-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 25 | mg | P |
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK3,MAP2K6,MAP3K21,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,ZAP70 | 36 | |||
| kinase-selectivity-class | AXL,EIF2AK3,GRK2,MAP2K6 | 4 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 18, 1976 | FDA | PHARMACIA AND UPJOHN |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | G02AD01 | GENITO URINARY SYSTEM AND SEX HORMONES OTHER GYNECOLOGICALS UTEROTONICS Prostaglandins |
| MeSH PA | D000019 | Abortifacient Agents |
| MeSH PA | D000020 | Abortifacient Agents, Nonsteroidal |
| MeSH PA | D010120 | Oxytocics |
| MeSH PA | D012102 | Reproductive Control Agents |
| CHEBI has role | CHEBI:75771 | Mus musculus metabolites |
| CHEBI has role | CHEBI:77746 | Homo sapiens metabolite |
Related Drugs by ATC class:
G02AD Prostaglandins 5 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Incomplete miscarriage | indication | 156072005 | |
| Induction of labor | indication | 236958009 | |
| Cervical ripening procedure | indication | 236959001 | |
| Pregnancy with abortive outcome | indication | 363681007 | |
| Hydatidiform mole, benign | indication | 417044008 | |
| Ocular hypertension | contraindication | 4210003 | DOID:9282 |
| Multiple pregnancy | contraindication | 16356006 | |
| Grand multipara | contraindication | 18656007 | |
| Disorder of lung | contraindication | 19829001 | DOID:850 |
| Glaucoma | contraindication | 23986001 | DOID:1686 |
| Disproportion between fetus and pelvis | contraindication | 25749005 | |
| Genital herpes simplex | contraindication | 33839006 | DOID:8704 |
| Depressive disorder | contraindication | 35489007 | |
| Placenta previa | contraindication | 36813001 | DOID:11060 |
| Inflammation of cervix | contraindication | 37610005 | DOID:2568 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Low blood pressure | contraindication | 45007003 | |
| Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
| Disseminated intravascular coagulation | contraindication | 67406007 | DOID:11247 |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Stenosis of cervix | contraindication | 83536006 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Uterine leiomyoma | contraindication | 95315005 | DOID:13223 |
| Female genital tract infection | contraindication | 125585007 | |
| Seizure disorder | contraindication | 128613002 | |
| Fetal distress | contraindication | 130955003 | |
| Spontaneous rupture of membranes | contraindication | 169734005 | |
| Asthma | contraindication | 195967001 | DOID:2841 |
| Deliveries by cesarean | contraindication | 200144004 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Abnormal uterine bleeding unrelated to menstrual cycle | contraindication | 312984006 | |
| Endocervical Lesions | contraindication | ||
| Gynecological Surgery | contraindication | ||
| Uterine Hypertonic Patterns | contraindication |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cattle | Abortion | Indication |
| Cattle | Unobserved (silent) estrus in lactating dairy cattle that have a corpus luteum | Indication |
| Cattle | Pyometra (chronic endometritis) | Indication |
| Cattle | Control of estrus and ovulation in estrous cycling cattle that have a corpus luteum | Indication |
| Horses | Control of estrus in estrus cycling mares and in clinically anestrous mares that have a corpus luteum | Indication |
| Swine | Parturition induction when injected within 3 days of normal predicted farrowing | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Prostin F2 Alpha Sterile Solution | Zoetis Inc. | 1 |
| Lutalyse Injection | Zoetis Inc. | 1 |
| LUTALYSE HighCon Injection | Zoetis Inc. | 1 |
| ProstaMate | Bimeda Animal Health Limited | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.79 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Prostaglandin F2-alpha receptor | GPCR | AGONIST | Kd | 8.40 | CHEMBL | CHEMBL | |||
| Prostaglandin D2 receptor 2 | GPCR | AGONIST | Ki | 6.40 | IUPHAR | ||||
| Prostaglandin E2 receptor EP3 subtype | GPCR | IC50 | 6.96 | CHEMBL | |||||
| Thromboxane A2 receptor | GPCR | AGONIST | Ki | 5.10 | IUPHAR | ||||
| Prostaglandin E2 receptor EP2 subtype | GPCR | AGONIST | Ki | 6 | IUPHAR | ||||
| Prostaglandin E2 receptor EP4 subtype | GPCR | IC50 | 5.38 | CHEMBL | |||||
| Prostaglandin D2 receptor | GPCR | IC50 | 5.35 | CHEMBL | |||||
| Prostaglandin E2 receptor EP1 subtype | GPCR | IC50 | 6.66 | CHEMBL | |||||
| Prostaglandin F2-alpha receptor | GPCR | Ki | 6.89 | CHEMBL | |||||
| Prostaglandin E2 receptor EP1 subtype | GPCR | AGONIST | Ki | 5.90 | IUPHAR | ||||
| Prostaglandin E2 receptor EP3 subtype | GPCR | AGONIST | Ki | 7.12 | IUPHAR | ||||
| Prostaglandin F2-alpha receptor | GPCR | EC50 | 7.90 | CHEMBL | |||||
| Prostaglandin E2 receptor EP2 subtype | GPCR | AGONIST | Ki | 5.60 | IUPHAR | ||||
| Prostaglandin E2 receptor EP4 subtype | GPCR | AGONIST | Ki | 6.20 | IUPHAR | ||||
| Prostaglandin D2 receptor 2 | GPCR | AGONIST | Ki | 6.20 | IUPHAR | ||||
| Prostaglandin E2 receptor EP3 subtype | GPCR | AGONIST | EC50 | 8.38 | IUPHAR | ||||
| Prostaglandin E2 receptor EP1 subtype | GPCR | AGONIST | Ki | 6.40 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| N0000008056 | NUI |
| D00081 | KEGG_DRUG |
| 23321 | RXNORM |
| 4018089 | VANDF |
| C0012471 | UMLSCUI |
| CHEBI:15553 | CHEBI |
| UGU | PDB_CHEM_ID |
| CHEMBL815 | ChEMBL_ID |
| DB12789 | DRUGBANK_ID |
| CHEMBL1200896 | ChEMBL_ID |
| D015237 | MESH_DESCRIPTOR_UI |
| 5280363 | PUBCHEM_CID |
| 3074 | INN_ID |
| 38562-01-5 | SECONDARY_CAS_RN |
| B7IN85G1HY | UNII |
| DB01160 | DRUGBANK_ID |
| 001308 | NDDF |
| 003958 | NDDF |
| 10192006 | SNOMEDCT_US |
| 387228004 | SNOMEDCT_US |
| 41001009 | SNOMEDCT_US |
| 58173009 | SNOMEDCT_US |
| C010714 | MESH_SUPPLEMENTAL_RECORD_UI |
| B7IN85G1HY | INXIGHT DRUGS |
Pharmaceutical products:
None